American Heart Journal
Volume 152, Issue 1 , Pages 86-92, July 2006

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

  • Anique Ducharme, MD, MSc

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Anique Ducharme, MD, MSc, Montreal Heart Institute, 5000 Belanger Street East, HIT 1C8 Montreal, Quebec, Canada.
    • ,
  • Karl Swedberg, MD, PhD

      Affiliations

    • Sahlgrenska University Hospital/Östra, Göteborg, Sweden
    • ,
  • Marc A. Pfeffer, MD, PhD

      Affiliations

    • Brigham & Women's Hospital, Boston, MA
    • ,
  • Alain Cohen-Solal, MD, PhD

      Affiliations

    • Cardiologie, Hôpital Beaujon, Clichy, France
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Aldo P. Maggioni, MD

      Affiliations

    • ANMCO Research Center, Florence, Italy
    • ,
  • Eric L. Michelson, MD

      Affiliations

    • AstraZeneca LP, Wilmington, DE
    • ,
  • John J.V. McMurray, MD

      Affiliations

    • Cardiology, Western Infirmary, Glasgow, UK
    • ,
  • Lars Olsson, MD, PhD

      Affiliations

    • Sahlgrenska University Hospital/Östra, Göteborg, Sweden
    • ,
  • Jean L. Rouleau, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • James B. Young, MD

      Affiliations

    • Medicine, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Bertil Olofsson

      Affiliations

    • AstraZeneca, Mölndal, Sweden
    • ,
  • Margareta Puu, PhD

      Affiliations

    • AstraZeneca, Mölndal, Sweden
    • ,
  • Salim Yusuf, MD, DPhil

      Affiliations

    • AstraZeneca, Mölndal, Sweden
    • ,
  • on behalf of the CHARM Investigators

      Affiliations

    • Cardiology, McMaster University, Hamilton, Ontario, Canada

Received 7 March 2005; accepted 21 June 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The CHARM was sponsored by AstraZeneca, Mölndal, Sweden.

PII: S0002-8703(05)00653-8

doi:10.1016/j.ahj.2005.06.036

American Heart Journal
Volume 152, Issue 1 , Pages 86-92, July 2006

Article Tools

* Image Usage & Resolution